Sequential Organ Failure Assessment SOFA   96789-3

LOINC Code


LOINC code96789-3
nameSequential Organ Failure Assessment SOFA
descriptionThe Sequential (or Sepsis-related) Organ Failure Assessment was developed as a means to asses multiple organ failure. As organ failure can develop or worsen over the length of a hospital stay, the SOFA is often used daily. The SOFA includes evaluations of six key systems, respiratory, cardiovascular, coagulation, central nervous system, liver and renal. This panel includes representative LOINC terms for the data points used to calculate each score as well as the six organ system scores and total SOFA score. Note that the specific LOINC terms used for each data point in a particular EHR may be different from those included in this panel.
statusACTIVE

Fully-Specified Name

componentSequential Organ Failure Assessment
property-
timePt  =  Point in time:  To identify measures at a point in time. This is a synonym for “spot” or “random” as applied to urine measurements.
system^Patient
scale-
methodSOFA

Additional Names

short nameSOFA

Basic Attributes

classPANEL.CLIN.RISK
type2  Clinical
order vs. observationOrder

Associated Observations

LOINC codes that represent optional associated observation(s) for a clinical observation or laboratory test. A LOINC term may represent a single associated observation or panel containing several associated observations.

History/Usage

first released
last updated2.70
last change typeADD  - added

Related Names

CLIN
CLIN.RISK
Pan
Panel
PANEL.CLINICAL
Panl
Pnl
Point in time
Random

Copyright © 2024 Regenstrief Institute, Inc. All Rights Reserved. To the extent included herein, the LOINC table and LOINC codes are copyright © 1995-2024, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. See https://loinc.org/license for the full LOINC copyright and license.

demo
request yours today
subscribe
start today
newsletter
free subscription

Thank you for choosing Find-A-Code, please Sign In to remove ads.